Hasil Pencarian  ::  Simpan CSV :: Kembali

Hasil Pencarian

Ditemukan 29 dokumen yang sesuai dengan query
cover
Boca Raton: CRC Press, Taylor & Francis Group, 2009
572.76 Des
Buku Teks  Universitas Indonesia Library
cover
cover
Pratama Wicaksana
"LATAR BELAKANG: Terapi ARV telah mengubah infeksi HIV dari penyakit yang mematikan menjadi penyakit kronik yang dapat dikendalikan. Salah satu efek samping terapi ARV adalah dislipidemia yang dapat meningkatkan risiko kardiovaskular. Studi tentang dislipidemia pada anak terinfeksi HIV di negara berkembang belum banyak dilakukan. TUJUAN: Tujuan penelitian ini adalah untuk mengetahui prevalens dislipidemia pada anak terinfeksi HIV dalam terapi ARV serta faktor risiko terkait. METODE: Studi potong lintang dilakukan di poliklinik anak RSCM dari bulan Januari hingga Juli 2019. Pemeriksaan profil lipid dikerjakan pada subyek yang memenuhi kriteria inklusi dan eksklusi. Data yang dikumpulkan adalah status gizi, stadium klinis saat awal diagnosis, status imunosupresi terakhir, nilai VL terakhir, paduan ARV terakhir, dan kombinasi ARV terakhir dari rekam medis. HASIL: Dari 96 subyek yang ikut alam penelitian ini, 52 (54,2%) mengalami dislipidemia. Prevalens dislipidemia pada kelompok terapi ARV lini 2 adalah 80%, sementara pada kelompok lini 1 adalah 39%. Terdapat hubungan yang bermakna antara penggunaan paduan ARV lini 2 dengan peningkatan risiko, yaitu sebesar 6,3 kali (p<0,01 IK95% [2,4-17,1]) untuk terjadi dislipidemia dibandingkan dengan paduan lini 1.KESIMPULAN: Prevalens dislipidemia pada anak terinfeksi HIV yang mendapatkan terapi ARV cukup tinggi dengan faktor risiko yaitu penggunaan paduan ARV lini 2.

INTRODUCTION: Antiretroviral therapy has changed the status of HIV infection from a high-mortality disease into a chronic disease. One of the consequences of long-term use of ARV is dyslipidemia that may progress into cardiovascular disease in the future. OBJECTIVE: The aim of the study was to seek the prevalence of dyslipidemia among HIV-infected children receiving ARV and related risk factors. METHODS: A cross-sectional study was conducted at pediatric outpatient clinic, RSCM, from January to July 2019. Lipid profile was examined on eligible subjects and data regarding nutritional status, clinical stadium at diagnosis, latest immuno supression status, latest VL value and latest ARV combination used were obtained from medical record. RESULTS: Of 96 subjects included, 52 (54,2%) subjects experienced dyslipidemia. Prevalence of dyslipidemia among second line and first line users were 80% and 39%,respectively. The use of second-line ARV medications was associated with 6,3 times (p=0,0 CI95%[2,4-17,1]) increase of risk for dyslipidemia compared to the use of first-line therapy. CONCLUSION: Prevalence of dyslipidemia among HIV-positive children on ARV is high with second-line ARV therapy being a risk facto."
Jakarta: Fakultas Kedokteran Universitas Indonesia, 2019
T58940
UI - Tesis Membership  Universitas Indonesia Library
cover
Eny Ida Riyanti
"ABSTRACT
Biomassa dari limbah lignoselulosa berpotensi sebagai sumber
produk biologi. Namun, salah satu kendala pemanfaatan hasil
hidrolisis biomassa adalah adanya senyawa inhibitor sehingga
penggunaan mikroorganisme tahan inhibitor sangat diperlukan
dalam proses fermentasi. Penelitian ini bertujuan untuk mengetahui
pengaruh campuran inhibitor terhadap Saccharomycess cerevisiae
strain I136 yang ditumbuhkan dalam medium yang mengandung
campuran inhibitor sintetis (asam asetat, asam format, furfural,
5-hydroxymethylfurfural/5-HMF, dan asam levulinat) dalam empatkonsentrasi yang berbeda dengan sumber karbon glukosa (50 g.l-1) dan xilosa (50 g.l-1) pada suhu 30oC. Pengamatan dilakukan terhadap parameter yang terkait dengan pertumbuhan strain ini dan produk hasil fermentasi. Hasil penelitian menunjukkan bahwa strain I136 tahan terhadap media BSL dengan nilai μmax 0,020/h. Peningkatan konsentrasi inhibitor dalam medium memperpanjang fase lag serta menurunkan produksi biomassa sel, produksi etanol, dan laju
pertumbuhan spesifik. Strain ini mampu mendetoksifikasi senyawa
furfural dan 5-HMF dan menghasilkan etanol tertinggi dengan nilai
(Y(p/s) 0,32 g.g-1 ketika ditumbuhkan dalam media BSL. Glukosa dapat digunakan yang ditandai dengan menurunnya konsentrasi glukosa dan meningkatnya konsentrasi sel biomassa. Sebaliknya, xilosa tidak digunakan dan konsentrasinya tetap sekitar 50 g.l-1. Produksi biomassa sel tertinggi dicapai ketika strain ini ditumbuhkan dalam media YNB dengan nilai Y(x/s) 0,25 g.g-1. Strain ini menghasilkan asam asetat sebagai produk samping yang dominan dan dapat mengubah furfural menjadi senyawa yang kurang toksik, yaitu hidroksi furfural. Hasil penelitian ini memberikan informasi awal tentang mekanisme toleransi dan berguna sebagai pabrik sel untuk produk biologi dengan menggunakan materi dari bahan berlignoselulosa."
Jakarta: Indonesian Agency for Agricultural Research and Development, 2017
630 IJAS 18:1 (2017)
Artikel Jurnal  Universitas Indonesia Library
cover
Fitri Santy Budiarso
"Pada tahun 2019 penderita diabetes di dunia diperkirakan 463 juta orang pada usia 20- 79 tahun. Angka diprediksi terns meningkat hingga mencapai 578 juta ditahun 2030 dan 700 juta ditahun 2045. Kayu Sarampa {Xylocarpus moluccensis (Lam.) M. Roen) secara tradisional telah digunakan untuk mengobati penderita diabetes oleh penduduk asli di Ratahan, Sulawesi Utara, Indonesia. Penelitian terdahulu terhadap ekstrak etil asetat buah Kayu Sarampa mempunyai penghambatan aktivitas enzim alfa-glukosidase. Penelitian ini beitujuaii untuk mengisolasi dan mengkarakterisasi senyawa dari ekstrak etil asetat kulit batang kayu sarampa dan uji penghambatan aktivitas enzim alfa glukosidase dan DPP-IV serta aktivitas antioksidan secara in-vitro. Kulit batang diekstraksi menggunakan metode reflux dengan pelarut heksana, etil asetat, dan metanol serta dilakukan skrining penghambatan alfa-glidcosidase dan antioksidan pada ekstrak yang diperoleh. Selanjutnya terhadap ekstrak etil asetat dilakukan pemisahan dan isolasi senyawa. Isolat yang didapat dikarakterisasi menggunakan 'H-NMR, '^C-NMR, 2DNMR, IR, LCMSMS dan diuji penghambatan aktivitas alfa-glukosidase, DPP-IV serta aktivitas antioksidan (DPPH dan FRAP). Hasil ekstraksi bertingkat menunjukkan bahwa ekstrak etil asetat dan ekstrak metanol kulit batang kayu sarampa kosentrasi 100 pg/mL memiliki penghambatan aktivitas enzim alfa-glukosidase berturut-tumt 49.7 dan 53,1 %, uji aktivitas antioksidan DPPH berturut- turut IC50 34,02 dm 16,51 pg/mL dan FRAP berturut-turut 131,84 dan 148,96 pmol Fe^Vg. Terhadap ekstrak etil asetat dilakukan pemisahan menggunakan kromatografi kolom diperoleh 10 ffaksi (A-J) dan diperoleh hasil fraksi D, F, G dan I kulit batang kayu sarampa memiliki penghambatan aktivitas enzim alfa-glukosidase dan aktivitas antioksidan (DPPH dan FRAP). Selanjutnya dilakukan isolasi lebih lanjut terhadap fraksi D dan F sehingga diperoleh 3 isolat (166, 177 dan 224). Hasil karakterisasi menunjukkan hasil isolat 166 adalah Xyloccensin E dan 177 adalali Ruangenin D serta isolat 224 adalah 2,3',5,5',7- pentahidroksiflavan. Penghambatan aktivitas enzim alfa-glukosidase berturut-turut untuk senyawa Xyloccensin E dan 2,3',5,5',7-pentahidroksiflavan dengan IC50 118,6 dan 55,1 pg/mL dan aktivitas antioksidan metode DPPH 54,69 dan 2,87 pg/mL serta kekuatan antioksidan FRAP sebesar 66,35 dan 213,82 pmol Fe^^^g. Ketiga isolat tersebut tidak memiliki penghambatan aktivitas terhadap enzim DPP-IV.

In 2019, there are an estimated 463 million people with diabetes in the world in the age of 20-79 years old. The numbers are predicted to continue to increase reaching 578 million in 2030 and 700 million in 2045. Kayu Sarampa {Xylocarpus moluccensis (Lam.) M. Roen) has traditionally been used to treat diabetics by indigenous people in Ratahan, North Sulawesi, Indonesia. The previous research on the ethyl acetate extract of the fhiit of Kayu Sarampa had an inhibition of alpha-glucosidase enzyme activity. This study aims to isolate and characterize the compounds from the ethyl acetate extract of Kayu Sarampa stem bark and to test the inhibition of alpha glucosidase and DPP-IV enzyme activity as well as in-vitro antioxidant activity. The stem bark was extracted using the reflux method with hexane, ethyl acetate, and methanol as the solvents and screening for alpha-glucosidase and antioxidant inhibition in the extracts that have been obtained. Furthermore, the ethyl acetate extract is separated and isolated from the compound. The isolates that have been obtained were characterized using IH-NMR, 13C-NMR, 2D-NMR, IR, LCMSMS and tested for inhibition of alpha-glucosidase activity, DPP-IV and antioxidant activity (DPPH and FRAP). The results of multilevel extraction showes that the ethyl acetate and the methanol extracts of Kayu Sarampa stem bark have the inhibition of alpha-glucosidase enzyme activity 49.7 dan 53.1 %, DPPH antioxidant activity test IC50 34.02 and 16.51 pg/mL and FRAP 131.84 dan 148.96 pmol Fe^^^g, respectively. The ethyl acetate extract is separated using column chromatography obtaining 10 fractions (A-J) and the results of the fractions D, F, G and I of Kayu Sarampa stem bark had inhibition of alpha-glucosidase enzyme activity and antioxidant activity (DPPH and FRAP). Thereafter, further solation is carried out on the D and F fractions obtaining 3 isolates (166, 177 and 224). The characterization results shows that the results of isolate 166 to be Xyloccensin E and 177 to be Ruangenin D and isolate 224 were 2,3',5,5',7-pentahidroxiflavan. Inhibition of alpha-glucosidase enzyme activity for Xyloccensin E and 2,3*,5,5',7-pentahidroxiflavan compounds with IC50 118.6 and 55.1 pg/ mL and antioxidant activity of DPPH methods 38.85 and 2,87 pg/mL and the antioxidant strength of FRAP were 66.35 and 213.82 pmol Fe^Vg respectively. The three isolates do not have inhibitory activity against the DPP-IV enzyme.
"
Depok: Fakultas Farmasi Universitas Indonesia, 2021
T59216
UI - Tesis Membership  Universitas Indonesia Library
cover
cover
Jemima Nurani Jacobs
"Ruang Lingkup dan Cara Penelitian: Peneliti di Indonesia sering mengalami kesulitan memperoleh bahan baku seperti petanda protein untuk menentukan 'berat molekul'. Salah satu petanda protein adalah inhibitor tripsin kacang kedelai (ITK). Penelitian ini bertujuan mengisolasi dan memurnikan ITK dari biji kacang kedelai (Glycine max), Isolasi dilakukan dengan cara ekstraksi asam, diikuti 'salting out, dialisis dan pengendapan aseton. Pemurnian dilakukan dengan kromatografi kolom pertukaran ion. Aktivitas ITK fraksi 'kasar' dan 'murni' diperiksa dengan mengamati pengaruh hambatan terhadap aktivitas enzimatik tripsin, dengan substrat azokasein (proteolitik) dan BAPA/BAPNA (amidase). Azokasein yang dipakai sebagai substrat reaksi tripsin disintesis sendiri. Penilaian kemurnian ITK ?kasar? dan 'murni', juga tripsin dilakukan dengan elektroforesis gel 'slab' SDS-poliakrilamid. Sebagai pembanding pada penelitian ini digunakan inhibitor tripsin produk Sigma.
Hasil dan Kesimpulan : Dari 100 g biji kacang kedelai kering panen, diperoleh 1,16 g isolat (ITK 'kasar') setara dengan 418,46 mg protein. Pemurnian lewat kolom pertukaran ion menghasilkan 2 fraksi dengan 'recovery' protein total minimal 63,7 %. Azokasein yang disintesis hasilnya berbeda bila jenis alkohol yang digunakan juga berbeda. Pada penelitian ini baik ITK 'kasar` maupun 'murni' memperlihatkan hambatan terhadap reaksi enzimatik tripsin. Hambatan 50 % terjadi pads rasio inhibitor/enzim yang bervariasi; ITK `murni' 1 memperlihatkan angka yang paling tinggi. Elektroforetogram menunjukkan bercak ITK 'murni' II identik dengan SBTI (Sigma).

Scope and Method of Study: The chemicals required for laboratory investigations are quite often difficult to obtain, e. g. the standard protein markers for molecular weight determination. Among the markers used for that purpose is the soybean trypsin inhibitor. This work was carried out to isolate and purify trypsin inhibitor from soybean (Glycine max) seeds (SBTI). The procedure included an acid extraction, followed by salting-out, dialysis and an acetone precipitation. Purification was carried out by ion-exchange column chromatography. The protein content of the isolate and of the purified substance was determined by spectrophotometer. The activities of the crude and of the purified soybean trypsin inhibitor were tested against trypsin activity. The trypsin used was obtained commercially. Trypsin's proteolytic activity was performed on azo-casein while its amidase activity was tested on BAPA/BAPNA. The azo-casein was synthesized in the laboratory. The purity of the crude and of the purified soybean trypsin inhibitors, and of the trypsin itself was examined on a slab SDS-polyacrylamide gel electrophoresis (SDS-PAGE).
Findings and Conclusions: From 100 g of dried soy-bean seeds, 1.16 of product was isolated (= 418.46 mg protein). Further purification on an ion-exchange column yielded two fractions, with a minimum of 63.7% protein recovered. The azo-casein synthesis revealed two different products depending on the grade of alcohol used in the process. The crude and the purified soybean trypsin inhibitors showed inhibitory effects towards trypsin. The fifty percent inhibition occurred at varied inhibitor/enzyme ratios, the highest was shown by the purified SBTI I. The electrophoretogram showed that the purified SBTI II was identical to the SBTI (Sigma).
"
Jakarta: Fakultas Kedokteran Universitas Indonesia, 1989
T-Pdf
UI - Tesis Membership  Universitas Indonesia Library
cover
"Proton pump inhibitors (PPls) are the most effective anti secretory drugs available for controlling gastric
acid acidity and volume. They are the drug of choice in the treatment for gastro esophageal reflux disease
(GERD), Helicobacter pylori eradication, peptic ulcer and non steroidal anti-inflammatory drug (NSAID)
gastropathy. For acute cases, on intravenous PPI is needed, especially for hospitalized patient. Recently,
intravenous pantoprazole represents an alternative to intravenous histamine-2 receptor antagonists. We
observed 2 patients who were treated with pantoprazole for duodenal ulcer; where one case had a
complication of bleeding with a history of long term use of NSAID. After two weelrs of treatment with
pantoprazole, significant lesion healing from endoscopy findings was achieved in both cases."
The Indonesian Journal of Gastroenterology Hepatology and Digestive Endoscopy Vol. 4 (1) April 2003 : 26-28, 2003
IJGH-4-1-Apr2003-26
Artikel Jurnal  Universitas Indonesia Library
cover
Klebl, Bert.
"This timely guide to kinase inhibitor drug development is the first to cover the entire drug pipeline, from target identification to compound development and clinical application. Edited by the pioneers in the field, on the drug development side this ready reference discusses classical medicinal chemistry approaches as well as current chemical genomics strategies. On the clinical side, both current and future therapeutic application areas for kinase inhibitor drugs are addressed, with a strong focus on oncology drugs.
Backed by recent clinical experience with first-generation drugs in the battle against various forms of cancer, this is crucial reading for medicinal, pharmaceutical and biochemists, molecular biologists, and oncologists, as well as those working in the pharmaceutical industry.
"
Weinheim: Wiley-VCH, 2011
e20394589
eBooks  Universitas Indonesia Library
cover
Chorniansyah Indriyanto Rahayu
"ABSTRAK
Latar Belakang : Hipertensi merupakan faktor resiko utama penyakit kardiovaskular,
terutama sindrom koroner akut dan stroke. Peningkatan konsumsi garam berhubungan
dengan kenaikan tekanan darah. Beberapa studi randomized-controlled trial (RCT)
menyatakan bahwa konsumsi rendah garam dapat menurunkan tekanan darah pada
populasi dewasa dengan atau tanpa hipertensi. Variabilitas tekanan darah selama 24 jam
bersifat dinamis. Peningkatan darah nokturnal memiliki makna klinis yang cukup besar,
merupakan salah satu prediktor dari penyebab kerusakan target organ, terutama kejadian
kardiovaskular dan stroke. Asupan garam dapat mempengaruhi variasi tekanan darah 24
jam, yang dalam hal ini dapat juga berpengaruh pada hipertensi nokturnal. Obat penyekat
EKA merupakan obat hipertensi lini pertama yang sering digunakan, terutama pada usia
muda dan hipertensi yang disertai sindrom metabolik, mengingat peranan Sistem Renin
Angiotensin memiliki peranan yang sangat penting dalam patofisiologi hipertensi. Asupan
garam juga memiliki peranan pada patofisiologi terjadinya hipertensi dalam sistem Renin
Angiotensin. Sedikit studi yang meneliti perpaduan obat penyekat EKA dengan asupan
rendah garam dalam menrunkan kejadian hipertensi. Oleh karena itu, Menarik untuk diteliti
pengaruh asupan garam dengan tekanan darah nokturnal pada pasien yang mengkonsumsi
obat penyekat EKA.
Tujuan : Menilai pengaruh asupan garam dengan tekanan darah nokturnal pada pasien
hipertensi yang mendapatkan terapi penyekat EKA.
Metode : Pasien poliklinik berusia 30 ? 50 tahun yang terdiagnosis hipertensi dan belum
pernah mendapatkan anti-hipertensi sebelumnya, dibagi menjadi 2 kelompok (asupan
rendah garam (Na <15 g/hari) dan asupan tinggi garam ≥15 g/hari). Kedua kelompok akan
diberikan lisinopril dan dilakukan pemeriksaan natrium urin 24 jam dan home blood
pressure monitoring..
Hasil Penelitian : Sebanyak 80 pasien hipertensi pasien hipertensi yang belum
mendapatkan terapi diikutsetakan dalam penelitian ini, yang terdiri dari 37 pasien
kelompok rendah garam dan 43 pasien kelompok tinggi garam. Kelompok pasien dengan
asupan rendah garam memliki delta penurunan darah nokturnal sistolik (p<0,001),
diastolic (p<0,001), dan rerata arteri (p<0,001) yang lebih besar dibandingkan pada
kelompok asupan tinggi garam. Rerata asupan garam pada penelitian ini sebesar 16,77
gram/hari. Pada analisa multivariat didapatkan delta penurunan tekanan darah tidak
dipengaruhi oleh usia, jenis kelamin, dislipidemia, IMT, dan durasi tidur.
Kesimpulan : Penelitian ini membuktikan asupan rendah garam dapat mempengaruhi efektivitas terapi penyekat EKA dalam menurunkan tekanan darah nokturnal. ABSTRACT
Background : Hypertension is one of important risk factor of cardiovascular
disease, especially acute coronary syndrome and stroke. High salt intake correlates
to high blood pressure. Some Randomized-Controlled-Trials stated that low salt
intake may decrease blood pressure in adult population with or without
hypertension. Blood pressure variation in 24 hours is not static but dynamically
changes. Increasing nocturnal blood pressure has significantly impacts, and become
one of predictor of target organ damage, especially cardiovascular events and
stroke. Salt intake may interferes both 24 hours blood pressure variation and
nocturnal blood pressure. Angiotensin Converting Enzyme(ACE) Inhibitors is first
drug of choice anti-hypertensive therapy, especially in young age and associated
with metabolic syndrome, due to important role of Renin Angiotensin Aldosterone
System in pathophysiology of hypertension, whereas salt intake also has role in that
system. Only few of studies that had proved combination of ACE Inhibitors and
low salt intake in decreasing blood pressure in hypertension population. Therefore,
it is so important to know the impact of low salt intake to nocturnal blood pressure
in hypertension patient treated with ACE Inhibitors.
Objectives : To know impact of low salt intake to nocturnal blood pressure in
hypertension patient treated with ACE Inhibitors.
Methods : There are 30 ? 50 years old ambulatory patients diagnosed as untreated
hypertension, divided into two groups (low salt intake (Na <15 grams/day) and high
salt intake (≥15 grams/day). Both of groups were administered Lisinopril 10mg and
underwent 24-hours sodium urine collection and home blood pressure monitoring
periodically.
Results : There are 80 ambulatory patients diagnosed as untreated hypertension,
consist of 37 patients in low salt intake group and 43 patients in high salt intake
group. Low salt intake group has lower nocturnal systolic (p<0.001), diastolic
(p<0.001), and mean arterial (p<0.001) blood pressure compared with high salt
intake group. Mean salt intake in this study was 16.77 grams/day. Multivariate
analyzes showed that the difference of decreasing nocturnal blood pressure was not
interfered by age, sex, dyslipidemia, BMI, and sleep duration.
Conclusion : This study has proved that low salt intake may interfere ACE Inhibitors therapy effectiveness in decreasing nocturnal blood pressure.;Background : Hypertension is one of important risk factor of cardiovascular
disease, especially acute coronary syndrome and stroke. High salt intake correlates
to high blood pressure. Some Randomized-Controlled-Trials stated that low salt
intake may decrease blood pressure in adult population with or without
hypertension. Blood pressure variation in 24 hours is not static but dynamically
changes. Increasing nocturnal blood pressure has significantly impacts, and become
one of predictor of target organ damage, especially cardiovascular events and
stroke. Salt intake may interferes both 24 hours blood pressure variation and
nocturnal blood pressure. Angiotensin Converting Enzyme(ACE) Inhibitors is first
drug of choice anti-hypertensive therapy, especially in young age and associated
with metabolic syndrome, due to important role of Renin Angiotensin Aldosterone
System in pathophysiology of hypertension, whereas salt intake also has role in that
system. Only few of studies that had proved combination of ACE Inhibitors and
low salt intake in decreasing blood pressure in hypertension population. Therefore,
it is so important to know the impact of low salt intake to nocturnal blood pressure
in hypertension patient treated with ACE Inhibitors.
Objectives : To know impact of low salt intake to nocturnal blood pressure in
hypertension patient treated with ACE Inhibitors.
Methods : There are 30 ? 50 years old ambulatory patients diagnosed as untreated
hypertension, divided into two groups (low salt intake (Na <15 grams/day) and high
salt intake (≥15 grams/day). Both of groups were administered Lisinopril 10mg and
underwent 24-hours sodium urine collection and home blood pressure monitoring
periodically.
Results : There are 80 ambulatory patients diagnosed as untreated hypertension,
consist of 37 patients in low salt intake group and 43 patients in high salt intake
group. Low salt intake group has lower nocturnal systolic (p<0.001), diastolic
(p<0.001), and mean arterial (p<0.001) blood pressure compared with high salt
intake group. Mean salt intake in this study was 16.77 grams/day. Multivariate
analyzes showed that the difference of decreasing nocturnal blood pressure was not
interfered by age, sex, dyslipidemia, BMI, and sleep duration.
Conclusion : This study has proved that low salt intake may interfere ACE Inhibitors therapy effectiveness in decreasing nocturnal blood pressure.;Background : Hypertension is one of important risk factor of cardiovascular
disease, especially acute coronary syndrome and stroke. High salt intake correlates
to high blood pressure. Some Randomized-Controlled-Trials stated that low salt
intake may decrease blood pressure in adult population with or without
hypertension. Blood pressure variation in 24 hours is not static but dynamically
changes. Increasing nocturnal blood pressure has significantly impacts, and become
one of predictor of target organ damage, especially cardiovascular events and
stroke. Salt intake may interferes both 24 hours blood pressure variation and
nocturnal blood pressure. Angiotensin Converting Enzyme(ACE) Inhibitors is first
drug of choice anti-hypertensive therapy, especially in young age and associated
with metabolic syndrome, due to important role of Renin Angiotensin Aldosterone
System in pathophysiology of hypertension, whereas salt intake also has role in that
system. Only few of studies that had proved combination of ACE Inhibitors and
low salt intake in decreasing blood pressure in hypertension population. Therefore,
it is so important to know the impact of low salt intake to nocturnal blood pressure
in hypertension patient treated with ACE Inhibitors.
Objectives : To know impact of low salt intake to nocturnal blood pressure in
hypertension patient treated with ACE Inhibitors.
Methods : There are 30 ? 50 years old ambulatory patients diagnosed as untreated
hypertension, divided into two groups (low salt intake (Na <15 grams/day) and high
salt intake (≥15 grams/day). Both of groups were administered Lisinopril 10mg and
underwent 24-hours sodium urine collection and home blood pressure monitoring
periodically.
Results : There are 80 ambulatory patients diagnosed as untreated hypertension,
consist of 37 patients in low salt intake group and 43 patients in high salt intake
group. Low salt intake group has lower nocturnal systolic (p<0.001), diastolic
(p<0.001), and mean arterial (p<0.001) blood pressure compared with high salt
intake group. Mean salt intake in this study was 16.77 grams/day. Multivariate
analyzes showed that the difference of decreasing nocturnal blood pressure was not
interfered by age, sex, dyslipidemia, BMI, and sleep duration.
Conclusion : This study has proved that low salt intake may interfere ACE Inhibitors therapy effectiveness in decreasing nocturnal blood pressure."
Fakultas Kedokteran Universitas Indonesia, 2015
SP-PDF
UI - Tugas Akhir  Universitas Indonesia Library
<<   1 2 3   >>